COVID-19 outbreak in Lombardy: Impact on reducing solid cancer diagnoses in 2020.
COVID-19
cancer diagnoses
population-based data
screening programmes
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
revised:
16
05
2022
received:
25
03
2022
accepted:
08
06
2022
pubmed:
16
6
2022
medline:
15
9
2022
entrez:
15
6
2022
Statut:
ppublish
Résumé
Our aim was to analyse, on a population level, the year-long decline in cancer diagnoses in the region of Lombardy (Italy), and to characterise the tumours with the greatest reduction in diagnosis by patient age, sex and tumour stage at diagnosis. We used the health care utilisation databases of the Lombardy region to identify cancer patients' characteristics (eg, sex, age) and cancer-related information (eg, cancer site, stage at diagnosis). The frequency of new cancer diagnoses in 2019 and 2020 were compared in terms of percentage differences in undiagnosed cases. We observed two peaks in the decline in cancer diagnoses: March to May 2020 (-37%) and October to December 2020 (-19%). The decline persisted over the course of 2020 and was higher in males and patients aged 74+. Diagnoses of all four common cancers analysed (female breast, lung, colorectal and prostate) remained below pre-pandemic levels. For breast and colorectal cancers, the decline in diagnoses was high in the age groups targeted by population-based screening programmes. We observed a reduction in localised stage cancer diagnoses for all four cancers. Our data confirm that timely monitoring of cancer diagnoses and interventions to prevent disruption of routine diagnostic services are needed to mitigate the impact of emergencies on cancer patients.
Identifiants
pubmed: 35704342
doi: 10.1002/ijc.34168
pmc: PMC9350168
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1502-1511Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Int J Cancer. 2022 Nov 1;151(9):1502-1511
pubmed: 35704342
JCO Clin Cancer Inform. 2020 Jul;4:657-665
pubmed: 32716647
Anticancer Res. 2020 Dec;40(12):7119-7125
pubmed: 33288611
Anticancer Res. 2021 Jun;41(6):3127-3130
pubmed: 34083306
Br J Cancer. 2021 Sep;125(6):798-805
pubmed: 34211120
Am J Clin Pathol. 2021 Jan 4;155(1):64-68
pubmed: 32995855
Br J Cancer. 2022 Aug;127(3):558-568
pubmed: 35501391
Lancet Oncol. 2020 Jun;21(6):750-751
pubmed: 32359403
Eur J Public Health. 2022 Apr 1;32(2):311-315
pubmed: 34935934
ESMO Open. 2021 Aug;6(4):100197
pubmed: 34474811
Acta Oncol. 2021 Jan;60(1):20-23
pubmed: 33287604
J Clin Pathol. 2021 Mar;74(3):187-189
pubmed: 32561524
ESMO Open. 2021 Apr;6(2):100055
pubmed: 33582382
Eur J Cancer Prev. 2022 Mar 1;31(2):204-214
pubmed: 34267109
In Vivo. 2020 Jun;34(3 Suppl):1651-1659
pubmed: 32503825
Dig Liver Dis. 2020 Aug;52(8):808-815
pubmed: 32425733
Curr Oncol. 2021 Oct 20;28(6):4247-4255
pubmed: 34898542
J Am Coll Surg. 2021 Apr;232(4):600-605
pubmed: 33346080
BJOG. 2021 Dec;128(13):2213-2214
pubmed: 34402585
Cancer. 2022 Mar 1;128(5):1048-1056
pubmed: 34866184
Chest. 2021 Jul;160(1):379-382
pubmed: 33417898
Dig Liver Dis. 2021 Jun;53(6):682-688
pubmed: 33726978
JCO Clin Cancer Inform. 2021 Sep;5:1028-1033
pubmed: 34648367
EJIFCC. 2021 Feb 28;32(1):69-77
pubmed: 33753976
JAMA Netw Open. 2020 Aug 3;3(8):e2017267
pubmed: 32749465
Hypertension. 2015 Mar;65(3):490-8
pubmed: 25624339
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
ESMO Open. 2022 Apr;7(2):100406
pubmed: 35219245
BMJ Open. 2021 May 18;11(5):e047567
pubmed: 34006554
Dig Liver Dis. 2020 Jul;52(7):695-699
pubmed: 32425732
Front Oncol. 2021 Jun 28;11:669786
pubmed: 34262861